Skip to content Skip to footer
Subscribe Now
Innocare Pharma
NEWS

InnoCare Pharma Reports NMPA’s NDA Acceptance of Zurletrectinib to Treat NTRK Fusion-Positive Solid Tumors

Shots: China’s NMPA has accepted NDA of zurletrectinib (ICP-723) for the treatment of pts (≥12yrs.) with advanced solid tumors having NTRK gene fusions In a registrational trial, zurletrectinib demonstrated favorable safety & strong efficacy, with the ability to overcome acquired resistance to the 1st generation TRK inhibitors in mentioned pts Zurletrectinib is a next-generation pan-TRK inhibitor…
April 17, 2025

Read more

VIEWPOINTS_John Orwin_2023
VIEWPOINTS

John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer

Shots: John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with Xencor He also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platform The interview gives an understanding of Atreca’s focus on…
June 20, 2023

Read more

Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumor Shots: The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 2021

Read more